We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Acal | LSE:ACL | London | Ordinary Share | GB0000055888 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 320.25 | 320.00 | 324.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
GlaxoSmithKline PLC (GSK) is "not in the market" for big merger and acquisition deals, but will continue to look for targeted investments and potential bolt-on acquisitions, Chief Executive Andrew Witty said Wednesday.
Speaking to reporters after the world's second-largest pharmaceutical company reported declining first-quarter profits, Witty declined to comment on speculation about specific companies, such as eyecare specialist Alcon Inc. (ACL), that have been highlighted as possible targets for GlaxoSmithKline.
Company Web site: www.gsk.com
-By Elena Berton, Dow Jones Newswires; 44 20 7842 9267; elena.berton@dowjones.com
1 Year Acal Chart |
1 Month Acal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
